• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The Obesity Paradox: How Real is It?

Video

Carl "Chip" Lavie, MD, author of the original book titled, "The Obesity Paradox" explains the paradox of metabolic health in the obese, how it wanes, and an essential element to maintain it.

The obesity paradox refers to the situation wherein, despite the known and marked ability of obesity to worsen nearly all cardiovsascular (CV) risk factors, particularly hypertension (HTN), type 2 diabetes, and dyslipidemia, and to increase the prevalance of CVD including HTN, heart failure, coronary heart disease, studies have shown that persons who are overweight or at least mildly obese who have stable CVD have better short- and moderate-term prognosis than do normal weight patients with the same CVD.

Dr Lavie explains the paradox, potential underlying mechanisms, and the critial role of cardiorespiratory fitness to maintain the balance.

__________________________________________________________________

Carl J Lavie, MD
Professor of Medicine,
Medical Director, Cardiac Rehabilitation and Prevention
Director, Stress Testing Laboratory, John Ochsner Heart and Vascular Institute,
Ochsner Clinical School - The University of Queensland School of Medicine

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.